A new market report projects strong growth ahead for the diagnostics industry, and Helio Genomics is named among the developments shaping it. According to Transparency Market Research, the global in vitro diagnostics (IVD) market is expected to grow from $114.3 billion in 2025 to $253.8 billion by 2036, a compound annual growth rate of 7.5%, driven in large part by rising demand for early disease detection.
Helio Genomics features in the report’s key developments for its May 2026 commercial partnership with Syneos Health, aimed at accelerating awareness and adoption of HelioLiver, the blood-based test for early detection of hepatocellular carcinoma (HCC).
The inclusion reflects growing momentum behind blood-based early cancer detection, exactly the space HelioLiver is built for, as the wider diagnostics industry shifts toward earlier, less invasive testing.
Source: OpenPR / Transparency Market Research. Read the full report summary.